NO20044250L - Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer - Google Patents

Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer

Info

Publication number
NO20044250L
NO20044250L NO20044250A NO20044250A NO20044250L NO 20044250 L NO20044250 L NO 20044250L NO 20044250 A NO20044250 A NO 20044250A NO 20044250 A NO20044250 A NO 20044250A NO 20044250 L NO20044250 L NO 20044250L
Authority
NO
Norway
Prior art keywords
diabetes
diseases
treatment
amide derivatives
heterocyclic amide
Prior art date
Application number
NO20044250A
Other languages
English (en)
Norwegian (no)
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Jianhua Guo
Mohamed Boudjelal
James W Zapf
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of NO20044250L publication Critical patent/NO20044250L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20044250A 2002-03-08 2004-10-07 Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer NO20044250L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36270202P 2002-03-08 2002-03-08
PCT/US2003/006784 WO2003075924A1 (fr) 2002-03-08 2003-03-07 Derives d'amide heterocyclique destines au traitement du diabete et d'autres maladies

Publications (1)

Publication Number Publication Date
NO20044250L true NO20044250L (no) 2004-11-03

Family

ID=27805215

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044250A NO20044250L (no) 2002-03-08 2004-10-07 Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer

Country Status (14)

Country Link
US (2) US7102000B2 (fr)
EP (1) EP1487443A4 (fr)
JP (1) JP2005530705A (fr)
KR (1) KR20050006126A (fr)
CN (1) CN1649586A (fr)
AU (1) AU2003225682A1 (fr)
CA (1) CA2478342A1 (fr)
IL (1) IL163952A0 (fr)
MX (1) MXPA04008733A (fr)
NO (1) NO20044250L (fr)
RU (1) RU2004129752A (fr)
TW (1) TW200306184A (fr)
WO (1) WO2003075924A1 (fr)
ZA (1) ZA200408057B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203367A3 (en) 1999-08-31 2004-12-28 Maxia Pharmaceuticals Inc San Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
EP1385465A4 (fr) * 2001-03-07 2005-09-07 Incyte San Diego Inc Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
EP1377559A4 (fr) * 2001-03-08 2005-09-28 Incyte San Diego Inc Molecules activant un recepteur rxr
WO2003016267A1 (fr) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Derives d'oxime pour le traitement de la dyslipidemie et de l'hypercholesterolemie
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
ZA200509355B (en) * 2003-04-18 2007-03-28 Incyte San Diego Inc Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
EP1566202A1 (fr) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Utilisation d'agonistes de la resistine pour le traitement de l'arthrite rheumatoide
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
WO2006025551A1 (fr) * 2004-08-30 2006-03-09 Takeda Pharmaceutical Company Limited Méthode de criblage
JP2009512637A (ja) 2005-09-30 2009-03-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしてのジヒドロ−[1h]−キノリン−2−オン誘導体
MX2010012626A (es) * 2008-05-20 2011-02-22 Merck Sharp & Dohme Produccion eficiente de proteinas heterologas utilizando inhibidores de manosil transferasa.
WO2012153775A1 (fr) 2011-05-10 2012-11-15 国立大学法人神戸大学 Dérivé de thioxothiazolidine ayant un effet inhibiteur sur la fonction ras
WO2015066647A2 (fr) 2013-11-03 2015-05-07 The Regents Of The University Of California Liquides ioniques pour administration transdermique de médicaments
JP6632720B2 (ja) * 2016-06-07 2020-01-22 三菱電機株式会社 温度推定方法
CA3035414C (fr) 2016-08-29 2022-02-22 The Regents Of The University Of California Formulations topiques a base d'especes ioniques pour le traitement de la peau
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (fr) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Procede pour la production d'acide 4-biphenylylacetique
EP0304493B1 (fr) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Derives d'hydroxystyrene
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
DE69227689T2 (de) 1991-07-22 1999-04-22 Pfizer Verfahren zur herstellung von (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl] brombenzol
ATE256653T1 (de) 1992-04-22 2004-01-15 Ligand Pharm Inc Verbindungen mit retinoid x receptorselektivität
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
JPH08506323A (ja) 1992-11-25 1996-07-09 ラ ホヤ キャンサー リサーチ ファウンデーション Rxrホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
MX9603414A (es) 1994-02-17 1997-03-29 American Home Prod Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa.
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
AU701790B2 (en) 1995-07-17 1999-02-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
CN1196730A (zh) 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
JP2000515506A (ja) 1996-07-08 2000-11-21 ガルデルマ リサーチ アンド デヴェロップメント エス エヌ シー アポプトーシスを誘発するアダマンチル誘導体及び該誘導体の抗癌剤としての使用
AU8747998A (en) 1997-08-21 1999-03-16 Takeda Chemical Industries Ltd. Anti-inflammatory agent
AU1052599A (en) 1997-11-12 1999-05-31 Institute Of Medicinal Molecular Design. Inc. Retinoid receptor agonists
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
WO2000010573A1 (fr) 1998-08-21 2000-03-02 Viropharma Incorporated Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
HUP0203367A3 (en) 1999-08-31 2004-12-28 Maxia Pharmaceuticals Inc San Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
CN1159305C (zh) 1999-11-12 2004-07-28 株式会社富吉摩托普拉泽兹 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
EP1385465A4 (fr) 2001-03-07 2005-09-07 Incyte San Diego Inc Derives heterocycliques pour le traitement du cancer et d'autres maladies proliferatives
EP1377559A4 (fr) 2001-03-08 2005-09-28 Incyte San Diego Inc Molecules activant un recepteur rxr
CA2438586A1 (fr) 2001-03-14 2002-09-19 Eli Lilly And Company Modulateurs des recepteurs x de retinoides
EP1392326B1 (fr) 2001-04-04 2009-09-09 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs du recepteur x du retinoide
WO2003016267A1 (fr) 2001-08-17 2003-02-27 Incyte San Diego Incorporated Derives d'oxime pour le traitement de la dyslipidemie et de l'hypercholesterolemie
EP1456187A4 (fr) * 2001-11-15 2005-02-09 Incyte San Diego Inc Heterocycles n-substitues pour le traitement de l'hypercholesterolemie, de la dyslipidemie et autres troubles du metabolisme, du cancer et de pathologies diverses
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
WO2004066952A2 (fr) 2003-01-29 2004-08-12 Incyte Corporation Derives du benzoxazole, du benzothiazole et du benzimidazole destines a traiter le cancer et d'autres maladies
ZA200509355B (en) 2003-04-18 2007-03-28 Incyte San Diego Inc Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases

Also Published As

Publication number Publication date
CA2478342A1 (fr) 2003-09-18
RU2004129752A (ru) 2005-05-10
CN1649586A (zh) 2005-08-03
TW200306184A (en) 2003-11-16
US20060241138A1 (en) 2006-10-26
EP1487443A4 (fr) 2006-04-12
AU2003225682A1 (en) 2003-09-22
MXPA04008733A (es) 2006-07-03
US7102000B2 (en) 2006-09-05
EP1487443A1 (fr) 2004-12-22
ZA200408057B (en) 2007-05-30
AU2003225682A2 (en) 2003-09-22
WO2003075924A1 (fr) 2003-09-18
JP2005530705A (ja) 2005-10-13
US20030216432A1 (en) 2003-11-20
KR20050006126A (ko) 2005-01-15
IL163952A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20055832D0 (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
NO20050570L (no) Nye forbindelser, preparater og fremgangsmater for behandling av inflammasjonssykdommer og -tilstander
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20055152D0 (no) Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser
NO20051493L (no) Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1400518T3 (da) Heterocycliske forbindelser og lægemidler
DK1673104T3 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
NO20053041D0 (no) Behandling av diabetes.
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
NO20053874L (no) Formulering og metoder for behandling av thrombocytemi
NO20054535D0 (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
NO20045554L (no) Fremgangsmate for behandling av diabetes
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
NO20022600D0 (no) Nye heterocykliske forbindelser og salter derav og medisinsk anvendelse av samme